Go for growth: the best bets in the US stockmarket
Nellie S. Huang and Anne Kates Smith of Kiplinger’s Personal Finance choose their favourites for 2021.
Hilton Worldwide Holdings
2020 has been a year to forget for this global hotel brand, which operates in over 100 countries. Earnings are expected to have fallen by 64%. “Revenue per available room” has slumped from $102 in 2019 to $47 today. But a “cash pot” of $3.5bn gives the firm the means to weather the storm and with any luck next year should bring a swift rebound in the travel sector. “A bet on a post-Covid-19 recovery.” $93
JPMorgan Chase
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Shares in this Wall Street giant have slipped by 15% this year as a weak economy and low interest rates have put the squeeze on financial services. However, the investment bank and trading division have enjoyed “record revenues” in 2020. JPMorgan Chase is a best-in-class operator and the recovery will boost earnings next year. In the meantime, the shares yield 3%. $103
This image-sharing social media app is used by people looking for some inspiration. Those stuck for interior-design ideas or deciding what new dish to cook can type in a few key words and find a gallery of ideas. The platform isn’t profitable yet but that could change soon: it has partnered with Shopify to allow advertisers to upload catalogues. Users will soon be “just a few clicks” between inspiration-hunting and purchase. $65
Tennant Company
This cleaning business makes industrial-grade floor scrubbers for clients such as supermarkets and warehouse operators. There is growing demand for its robotic floor cleaner. They don’t come cheap: $60,000 compared to about $15,000 for a human-operated equivalent. Yet more and more retailers are finding that the cost savings in terms of staff time are worth it, with Walmart ordering 1,400 last March. $62
Twilio
This communications-software specialist helps businesses stay in touch with their customers. When you receive an automatic text reminding you about an appointment or chat with a robot on a firm’s website to organise a delivery, Twilio may be behind it. Social distancing has turbocharged the rush online. Twilio’s annual sales growth could keep topping 30% for four years. $292
UPS
Soaring e-commerce demand and the complications of a pandemic are likely to expose “capacity limitations” in the global logistics business next year. That will mean price hikes, and this delivery behemoth is well placed to cash in. UPS is a two-way bet: a vaccine-enabled recovery will bring new business, but if the world takes longer to return to normal then that will just mean even more reliance on online ordering and package delivery. $167
Stryker
Stryker makes medical devices such as surgical kit and implants used for joint replacements. The cancellation of so many elective surgeries has made this a rocky year but there should be a recovery in 2021. Stryker is strong across developed markets and China is also promising. “A core position for growth-orientated investors.” $213
Wayfair
This online home goods and furniture seller is going from strength to strength. Its most recent quarterly results comfortably beat analysts’ expectations, with the group adding “ten million more active customers” than it had 12 months ago. Evidently those looking for a comfy couch no longer feel the need to try before they buy. That trend is likely to continue as traditional furniture stores close and more of the industry moves online. Deutsche Bank sees scope for a 16% rise in the stock. $301
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Ben Cohen: The Ben & Jerry’s co-founder who wants to break away from Unilever
Ben Cohen of Ben & Jerry’s ice cream is seeking to break away from Unilever, the conglomerate he sold out to in 2000. It’s a battle for the soul of the brand synonymous with corporate do-gooding.
By Jane Lewis
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Chemring Group: an explosive investment opportunity in defence
European states are raising their military spending, and Chemring Group looks well placed to profit
By Rupert Hargreaves
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves